|
|
 |
|
Viewing report
|
|
|
|
Japan Generics Market
Frost & Sullivan, March 2011, Pages: 50
This research study presents an overview and analysis of the generics market in Japan from the time period 2009 to 2014. It goes over government regulations, healthcare system dynamics, disease and age demographics. Along with this coverage, the study also outlines market drivers and restraints, market engineering measurements, market size and growth for both the pharmaceutical and generics markets in Japan. The study ends with a competitive market analysis, which includes the top domestic companies in the Japan generics market. Additionally, it lists the top ten pharmaceutical companies in Japan and any actions they have taken to gain or improve market share in the generics market
Research Overview
This Frost & Sullivan research service titled Japan Generics Market provides an overview of the generics and pharmaceutical markets, government regulations, healthcare system and regulations, market drivers and restraints, revenue forecasts, competitive market analysis, patent expirations, and industry growth opportunities.
Market Overview
A Rise in the Number of the Aged in Japan to Propel the $5.40 Billion Generics Market towards $7.50 Billion in 2014
Can Japan Beat Back Competition to Hold on to its No.2 Position in the Global Pharmaceuticals Market?
In 2009, 22.7 per cent of the population in Japan was aged 65 years and above and by 2050, this share is likely to increase to 40 per cent. While this is alarming news for the nation’s developers, generic drug companies will not be complaining. The rise in the population of the elderly will place additional healthcare burden on the government, prompting them to step up their support of generic drugs in the form of favourable policies. “The government is aiming to increase the market share by volume of generic drugs from 17.0 per cent in 2009 to 30.0 per cent by 2012,” says the analyst of this research. “It has also made the drug registration process for generics quicker and easier to increase availability in the market.” The proactive government support, higher investments and fast growth rate of the generics market have fostered partnerships and collaborations between foreign pharmaceutical companies and their domestic generics counterparts, making Japan a potentially lucrative generics market.
Despite this thrust given to generic drugs by the Government, branded drugs heavily dominate the pharmaceuticals market in Japan, with both doctors and consumers preferring the latter to the former. While patients prefer them for their easy availability, doctors prescribe them partly due to the comprehensive universal healthcare in Japan. It will be a stiff challenge to change the public’s negative perception of generic drugs; therefore, the companies have to strive to educate the public and healthcare professionals, encourage greater numbers of generic prescriptions, and provide incentives for industry entry and growth. Generic pharmaceuticals will require robust government backing to persuade patients and doctors to increase their generics usage, but they should also make an effort to enhance their market visibility.
“In addition to taking advantage of government incentives that encourage generic drug registration and production, generics companies must show their products are as effective and safe as the products offered by their branded competitors,” notes the analyst. “The wave of blockbuster drug patent expirations that will occur over the next five years creates an opportunity for generics companies to increase their product range and gain market share across multiple therapeutic areas.”
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
